The US Food and Drug Administration has cleared Tyra's Investigational New Drug application to proceed with a Phase 1 clinical study of TYRA-430. The Phase 1 study will be a multicenter ...
Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, ...
• ELRIG Research & Innovation 2025 takes place in London, UK from 10–11 March • Event will focus on ‘Big molecules to big ...
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...
Additional details on the meeting can be found at the WORLD Symposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing ...
Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.
India's competitive advantage also lies in the increased success rate of Indian companies in getting Abbreviated New Drug Application (ANDA) approvals. India also offers vast opportunities in R&D as ...